NAD+ 1000 mg

Nicotinamide adenine dinucleotide is not a peptide. It is a dinucleotide: two ribonucleotides, one bearing nicotinamide and one adenine, joined through their 5′-phosphate groups by a pyrophosphate bridge. The nicotinamide is attached to its ribose in the beta configuration. The plus sign in NAD+ denotes a formal charge on the nicotinamide ring; it does not specify a salt form.

Reduction of the nicotinamide ring produces NADH, forming the NAD+/NADH redox pair. Both oxidation states absorb near 260 nm through the adenine portion, while the reduced form also absorbs near 340 nm. Tracking that second signal is a standard way to follow enzyme turnover in biochemical assays. This analytical distinction does not make NADH interchangeable with NAD+.

In cells, NAD+ can be assembled de novo from tryptophan, from nicotinic acid through the Preiss–Handler pathway, or by recycling nicotinamide through NAMPT and NMNAT. NAD+ also acts as a co-substrate for enzymes including sirtuins and PARPs. Molecular formulae and masses depend on the depicted protonation and salt form; this 1000 mg listing does not assign a counter-ion or analytical specification from a general molecular description.

The literature on intracellular NAD+ biochemistry must be separated from studies that administer intact NAD+. The human literature on the precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) is a third category. They are different molecules with different transport and metabolism, so precursor findings are not studies of this intact dinucleotide.

Grant and colleagues described their plasma-and-urine metabolome investigation as a pilot study. The later randomised study by Yu and colleagues examined a specific heart-failure population: a cardiac-function endpoint favoured the NAD+ arm, while several secondary clinical endpoints did not reach significance. The authors called for larger multicentre validation. These findings cannot establish general anti-ageing or wellness benefits.

The precursor work likewise needs precise interpretation. Martens and colleagues measured cellular NAD+ after NR supplementation. Elhassan and colleagues observed changes in the muscle NAD+ metabolome while mitochondrial bioenergetics remained unchanged. These are biochemical endpoints, not interchangeable clinical outcomes. Read precursor trials as adjacent evidence, not as tests of this 1000 mg research vial.